合肥立方制药股份有限公司关于2022年限制性股票激励计划部分限制性股票回购注销完成的公告

Core Viewpoint - The company has completed the repurchase and cancellation of a total of 1,078,318 restricted stocks due to the failure to meet performance assessment targets and the departure of certain incentive recipients [2][10][14]. Group 1: Stock Repurchase Details - The repurchase involved 87 incentive recipients, with 66 from the initial grant and 22 from the reserved grant, resulting in a total of 1,078,318 shares, which is 0.56% of the company's total share capital before the repurchase [2][10]. - The total funds allocated for this repurchase amount to 7,850,155.04 yuan, with an additional interest of 477,667.87 yuan, bringing the total to 8,327,822.91 yuan, sourced from the company's own funds [2][13]. - The repurchase price for the stocks was set at 7.28 yuan per share, which includes the bank's interest for the remaining incentive recipients whose performance did not meet the 2024 targets [2][12]. Group 2: Approval and Implementation Process - The stock incentive plan was approved by the company's board and supervisory committee in August 2022, with subsequent public announcements and confirmations made through various meetings [3][4][5]. - The first grant of restricted stocks was completed on October 19, 2022, and the reserved grant was completed on July 20, 2023 [5][6]. - The cancellation of the stocks was confirmed by the China Securities Depository and Clearing Corporation on July 23, 2025, following the completion of the repurchase process [14]. Group 3: Impact on Company Structure - Following the cancellation, the company's total share capital decreased from 191,260,500 shares to 190,182,182 shares [14][15]. - The management team has stated that this repurchase will not have a significant impact on the company's financial status or operational performance [15].